68Ga-PSMA PET/CT in prostate cancer

J R García Garzón; M de Arcocha Torres; R Delgado-Bolton; F Ceci; S Alvarez Ruiz; J Orcajo Rincón; A P Caresia Aróztegui; M J García Velloso; A M García Vicente; Oncology Task Force of Spanish Society of Nuclear Medicine and Molecular Imaging

doi:10.1016/j.remn.2017.07.004

⁶⁸Ga-PSMA PET/CT in prostate cancer

Rev Esp Med Nucl Imagen Mol (Engl Ed). 2018 Mar-Apr;37(2):130-138. doi: 10.1016/j.remn.2017.07.004. Epub 2017 Sep 21.

[Article in English, Spanish]

Authors

J R García Garzón¹, M de Arcocha Torres², R Delgado-Bolton³, F Ceci⁴, S Alvarez Ruiz⁵, J Orcajo Rincón⁶, A P Caresia Aróztegui⁷, M J García Velloso⁸, A M García Vicente⁹; Oncology Task Force of Spanish Society of Nuclear Medicine and Molecular Imaging

Affiliations

¹ Unitat PET/TC CETIR-ERESA, Esplugues de Llobregat, Barcelona, España. Electronic address: [email protected].
² Unidad de Radiofarmacia, Hospital Universitario Marques de Valdecilla, Santander, España.
³ Departamento de Diagnóstico por Imagen y Medicina Nuclear, Hospital San Pedro-Centro de Investigación Biomédica de La Rioja (CIBIR), Logroño, La Rioja, España.
⁴ Department of Surgical Sciences, University of Bologna, Bolonia, Italia.
⁵ Servicio de Medicina Nuclear, Hospital Universitario Miguel Servet, Zaragoza, España.
⁶ Servicio de Medicina Nuclear, Hospital General Universitario Gregorio Marañón, Madrid, España.
⁷ Servicio de Medicina Nuclear, Hospital Parc Taulí, Sabadell, Barcelona, España.
⁸ Servicio de Medicina Nuclear, Clínica Universidad de Navarra, Pamplona, España.
⁹ Servicio de Medicina Nuclear, Hospital General Universitario, Ciudad Real, España.

PMID: 28941866
DOI: 10.1016/j.remn.2017.07.004

Abstract

Positron emission tomography/computed tomography (PET/CT) with ⁶⁸Ga-PSMA is a non-invasive diagnostic technique to image prostate cancer with increased prostate-specific membrane antigen (PSMA) expression. PSMA is a transmembrane protein present in all prostatic tissues. Increased PSMA expression is seen in several malignancies, although prostate cancer is the tumour where it presents higher concentrations. Almost all prostate adenocarcinomas show PSMA expression in most of lesions, primary and metastatic. Immunohistochemistry has demonstrated that the expression of PSMA increases in patients with de-differentiated, metastatic or hormone-refractory tumours. Moreover, the expression level of PSMA has a prognostic value for disease outcome. PET measures the three-dimensional distribution of ⁶⁸Ga-PSMA, producing semi-quantitative images that allow for non-invasive assessment of PSMA expression.

Keywords: Cáncer de próstata; PET/CT; PET/TC; PSA; PSMA; Prognosis; Pronóstico; Prostate cancer; Recidiva; Relapse.

Publication types

Review

MeSH terms

Adenocarcinoma / chemistry
Adenocarcinoma / diagnostic imaging*
Adenocarcinoma / pathology
Adenocarcinoma / therapy
Aged
Edetic Acid / analogs & derivatives*
Edetic Acid / chemical synthesis
Edetic Acid / pharmacokinetics
Follow-Up Studies
Gallium Isotopes
Gallium Radioisotopes / pharmacokinetics*
Gene Expression Regulation, Neoplastic
Humans
Male
Middle Aged
Neoplasm Staging
Oligopeptides / chemical synthesis
Oligopeptides / pharmacokinetics*
Positron Emission Tomography Computed Tomography / methods*
Prognosis
Prostate-Specific Antigen / analysis
Prostate-Specific Antigen / biosynthesis
Prostate-Specific Antigen / genetics
Prostatic Neoplasms / chemistry
Prostatic Neoplasms / diagnostic imaging*
Prostatic Neoplasms / pathology
Prostatic Neoplasms / therapy
Radiometry
Radiopharmaceuticals / chemical synthesis
Radiopharmaceuticals / pharmacokinetics*
Recurrence
Sensitivity and Specificity
Tissue Distribution
Tumor Burden

Substances

Gallium Isotopes
Gallium Radioisotopes
Oligopeptides
Radiopharmaceuticals
gallium 68 PSMA-11
Gallium-68
Edetic Acid
Prostate-Specific Antigen